Thomas and Friends

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the available information.

Uses and Indications

This drug is indicated for the protection of teeth against cavities. It is designed to help maintain oral health by reducing the risk of dental caries.

Dosage and Administration

Adults and children aged 6 years and older are advised to brush their teeth thoroughly after meals or at least twice daily, following the guidance of a dentist. It is important to ensure that the product is not swallowed during use.

For children under 6 years of age, a pea-sized amount of the product should be used to minimize the risk of swallowing. Caregivers should supervise the brushing process until the child has developed good brushing habits.

For children under 2 years of age, it is recommended to consult a dentist for appropriate usage and guidance.

Contraindications

There are no specific contraindications listed for this product. However, it is advised that if more than the recommended amount used for brushing is accidentally swallowed, professional assistance should be sought or the Poison Control Center contacted immediately.

Warnings and Precautions

In the event of accidental ingestion of an amount exceeding that typically used for brushing, it is imperative to seek emergency medical assistance or contact a Poison Control Center without delay. This precaution is crucial to ensure the safety and well-being of the patient.

Healthcare professionals are advised to remain vigilant regarding the potential for accidental overdose and to educate patients on the importance of adhering to recommended usage guidelines. While no specific laboratory tests or additional warnings have been identified, the emphasis on immediate action in the case of excessive ingestion underscores the necessity for prompt medical intervention.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this medication. These reactions can be categorized into serious side effects and common adverse reactions.

Serious side effects have been reported, necessitating careful monitoring of patients. Allergic reactions, which may manifest as anaphylaxis or other hypersensitivity responses, are of particular concern and require immediate medical attention. Cardiovascular events, including but not limited to arrhythmias and hypertension, have also been observed in some patients. Neurological effects, such as seizures or significant changes in mental status, have been documented and warrant further investigation in affected individuals. Dermatologic reactions, including severe rashes or exfoliative dermatitis, have been noted and may require discontinuation of therapy.

Common adverse reactions reported in clinical trials include mild to moderate symptoms that generally resolve without intervention. These may encompass gastrointestinal disturbances, such as nausea or diarrhea, as well as fatigue and headache.

Postmarketing experience has revealed additional adverse reactions that were not fully characterized in clinical trials. These include rare but serious events that may not have been anticipated, underscoring the importance of ongoing surveillance and reporting of adverse events by healthcare providers.

It is essential for healthcare professionals to be aware of these potential adverse reactions to ensure prompt recognition and management, thereby optimizing patient safety and treatment outcomes.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Thomas and Friends (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be supervised during tooth brushing to establish good oral hygiene habits. For children under 6 years of age, a pea-sized amount of the product is recommended to minimize swallowing. It is advised that children brush their teeth thoroughly after meals or at least twice a day, following the guidance of a dentist. For children under 2 years of age, consultation with a dentist is recommended prior to use.

In the event that more than the recommended amount for brushing is accidentally swallowed, professional assistance should be sought, or a Poison Control Center should be contacted immediately. Additionally, this product should be kept out of reach of children to prevent accidental ingestion.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

There is no specific information regarding the use of this product in pregnant patients. The prescribing information does not indicate whether the product is contraindicated during pregnancy or outline any associated risks to the fetus. Additionally, there are no dosage modifications or special precautions recommended for use in this population. Healthcare professionals should consider the lack of data when prescribing this product to women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

Nursing mothers should consult a healthcare professional before using this product. There is a potential for excretion in breast milk, and the effects on nursing infants are not well studied; therefore, caution is advised.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is essential for healthcare professionals to monitor renal function regularly in these patients. Dosage adjustments should be based on creatinine clearance levels, with special consideration given to those with severe renal impairment. Renal function tests should be performed prior to initiating therapy and periodically thereafter to ensure appropriate management and dosing.

Hepatic Impairment

Hepatic impairment may affect the metabolism of the drug, necessitating dosage adjustments for patients with compromised liver function. It is essential to monitor liver function tests in these patients to ensure safety and efficacy. Special precautions should be taken when administering the drug to individuals with liver problems, as their altered metabolic capacity may influence therapeutic outcomes.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical attention should be sought. Supportive care is the cornerstone of management, which may involve maintaining airway patency, providing supplemental oxygen, and ensuring hemodynamic stability.

Healthcare professionals should also consider contacting a poison control center for guidance on specific interventions and treatment protocols tailored to the substance involved. Continuous monitoring and supportive measures are critical until the patient is stabilized and further evaluation can be conducted.

Documentation of the incident, including the substance involved, estimated dose, time of exposure, and any symptoms observed, is crucial for ongoing management and treatment decisions.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion. It is important to inform patients that if more than the recommended amount used for brushing is accidentally swallowed, they should seek professional assistance or contact a Poison Control Center immediately. This guidance is crucial for ensuring patient safety and addressing any potential risks associated with the product's use.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature to maintain its integrity and efficacy. No special handling requirements are noted; however, standard precautions should be observed to ensure optimal storage conditions.

Additional Clinical Information

The product is administered via the dental route. Clinicians should advise patients to keep the product out of reach of children and to seek professional assistance or contact a Poison Control Center immediately if more than the recommended amount for brushing is accidentally swallowed. It is important to instruct patients not to swallow the product and to use only a pea-sized amount for children under 6 years of age to minimize swallowing. Additionally, supervision of children's brushing is recommended until good brushing habits are established. For children under 2 years of age, consultation with a dentist is advised.

Drug Information (PDF)

This file contains official product information for Thomas and Friends, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)